ORMP Valuation

Oramed Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.080

-0.04(-1.887%)1D

Overview
Forecast
Valuation
Earnings

ORMP Relative Valuation

ORMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORMP is overvalued; if below, it's undervalued.

Historical Valuation

Oramed Pharmaceuticals Inc (ORMP) is now in the Fair zone, suggesting that its current forward PS ratio of 43.30 is considered Fairly compared with the five-year average of -10.93. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between 0.56 to 5.89 according to relative valuation methord.

Relative Value

Fair Zone

0.56-5.89

Current Price：2.08

Fair

-6.12

Trailing

Forward

0.00

EV/EBITDA

Oramed Pharmaceuticals Inc. (ORMP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.47. The thresholds are as follows: Strongly Undervalued below -8.77, Undervalued between -8.77 and -5.12, Fairly Valued between 2.19 and -5.12, Overvalued between 2.19 and 5.84, and Strongly Overvalued above 5.84. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.58

EV/EBIT

Oramed Pharmaceuticals Inc. (ORMP) has a current EV/EBIT of 0.58. The 5-year average EV/EBIT is -2.56. The thresholds are as follows: Strongly Undervalued below -16.63, Undervalued between -16.63 and -9.59, Fairly Valued between 4.47 and -9.59, Overvalued between 4.47 and 11.50, and Strongly Overvalued above 11.50. The current Forward EV/EBIT of 0.58 falls within the Historic Trend Line -Fairly Valued range.

43.30

Oramed Pharmaceuticals Inc. (ORMP) has a current PS of 43.30. The 5-year average PS is 81.87. The thresholds are as follows: Strongly Undervalued below -56.86, Undervalued between -56.86 and 12.50, Fairly Valued between 151.24 and 12.50, Overvalued between 151.24 and 220.60, and Strongly Overvalued above 220.60. The current Forward PS of 43.30 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Oramed Pharmaceuticals Inc. (ORMP) has a current P/OCF of 0.00. The 5-year average P/OCF is -5.75. The thresholds are as follows: Strongly Undervalued below -30.44, Undervalued between -30.44 and -18.09, Fairly Valued between 6.60 and -18.09, Overvalued between 6.60 and 18.95, and Strongly Overvalued above 18.95. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Oramed Pharmaceuticals Inc. (ORMP) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.03. The thresholds are as follows: Strongly Undervalued below -18.58, Undervalued between -18.58 and -10.80, Fairly Valued between 4.74 and -10.80, Overvalued between 4.74 and 12.51, and Strongly Overvalued above 12.51. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Oramed Pharmaceuticals Inc (ORMP) has a current Price-to-Book (P/B) ratio of 0.60. Compared to its 3-year average P/B ratio of 0.84 , the current P/B ratio is approximately -27.88% higher. Relative to its 5-year average P/B ratio of 1.96, the current P/B ratio is about -69.27% higher. Oramed Pharmaceuticals Inc (ORMP) has a Forward Free Cash Flow (FCF) yield of approximately -12.10%. Compared to its 3-year average FCF yield of -13.18%, the current FCF yield is approximately -8.22% lower. Relative to its 5-year average FCF yield of -12.14% , the current FCF yield is about -0.33% lower.

0.60

P/B

Median3y

0.84

Median5y

1.96

-12.10

FCF Yield

Median3y

-13.18

Median5y

-12.14

Competitors Valuation Multiple

The average P/S ratio for ORMP's competitors is 7.45, providing a benchmark for relative valuation. Oramed Pharmaceuticals Inc Corp (ORMP) exhibits a P/S ratio of 43.30, which is 481.32% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ORMP.O

Oramed Pharmaceuticals Inc

Acumen Pharmaceuticals Inc

Loss

86.01M

ATRA.O

Atara Biotherapeutics Inc

Performance Decomposition

Market capitalization of ORMP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ORMP in the past 1 year is driven by Unknown.